XML 154 R97.htm IDEA: XBRL DOCUMENT v3.25.0.1
Principal alliances - Agreements on the commercialization of Beyfortus™ (nirsevimab, previously MEDI8897) in the US (Details) - EUR (€)
€ in Millions
 1 Months Ended 3 Months Ended 12 Months Ended
Jul. 31, 2023
Nov. 30, 2022
Mar. 31, 2017
Sep. 30, 2019
Dec. 31, 2024
Dec. 31, 2023
Dec. 31, 2022
Disclosure of Principal Alliances [Line Items]              
Collaboration agreements, upfront payment     € 120        
Other non-current liabilities [1]         € 2,334 € 2,340 € 519
Antibodies Collaboration agreement | AstraZeneca              
Disclosure of Principal Alliances [Line Items]              
Collaboration agreements, development milestone payment       € 30      
Collaboration agreements, regulatory milestone payment € 65 € 25          
Commitments related to milestone payments for projects under collaboration agreements           375  
Accruals         100    
Collaboration Agreements, Amount Paid         25    
Collaboration Agreements, Amount Made         € 50    
Intangible assets and goodwill           1,600  
Total financial liabilities measured at fair value           1,600  
Antibodies Collaboration agreement | AstraZeneca | Major territories              
Disclosure of Principal Alliances [Line Items]              
Percentage of profits arising from commercial operations         5000.00%    
Antibodies Collaboration agreement | AstraZeneca | Other territories              
Disclosure of Principal Alliances [Line Items]              
Percentage of profits arising from commercial operations         25.00%    
Antibodies Collaboration agreement | Swedish Orphan Biovitrum AB              
Disclosure of Principal Alliances [Line Items]              
Other non-current liabilities         € 2,007    
Increase through remeasurement of financial liability         291 541  
Immuno-oncology collaboration agreement | Regeneron Pharmaceuticals, INC | Major Collaboration Agreement              
Disclosure of Principal Alliances [Line Items]              
Proceeds from collaboration agreements         € 117 € 196 € 952
[1] (a)Includes derivative financial instruments: €121 million as of December 31, 2024, €164 million as of December 31, 2023, €232 million as of December 31,
2022.
The figure as of December 31, 2024 includes €2,007 million for the liability in respect of royalties payable to Sobi on net sales of Beyfortus (nirsevimab) in
the United States (see Note C.2.). Given the method used to calculate royalties payable, an increase or decrease in sales forecasts would lead to a
proportionate change in the amount of the liability. The nominal value of payments estimated to be due within more than one year but less than five
years is €1,140 million; the nominal value of payments estimated to be due after more than five years is €2,792 million.